European Archives - Page 583 of 1192 - European Medical Journal

EMJ Oncology 10 [Supplement 3] 2022

In this interview, they discuss the role of direct oral anticoagulants (DOAC) as a treatment for cancer-associated thrombosis (CAT)…

Levelling the Playing Field

In this episode, Jonathan is joined by Dr Steve Wexner, Chairman of the Department of Colorectal Surgery at the Cleveland Clinic, Miami, Florida, USA.

The return of the vaccines

The pandemic revived all areas of vaccine development. Read more about the effect of Covid-19 on investment, development and commercialisation of vaccines.

R&D progress on the rise

Pharmaceutical R&D saw sustained growth in clinical trial activity and a record number of novel active substances launched in 2021, according to a new report from IQVIA.

Judy Stewart and Vincent Steine

Vaccines, leadership and blockchain

A chat with Judy Stewart (GSK) and Vincent Steine in the first episode of a new season of GOLD podcasts. Tune in to find out more about vaccines, pharma and blockchain.

Microbiol-Infect-Dis-CP-940x572

Aspergillus terreus Peritonitis in a Child on Continuous Ambulatory Peritoneal Dialysis: A Case Report from Pakistan

Continuous ambulatory peritoneal dialysis (CAPD) is a well-known management technique for paediatric Stage 5 chronic kidney disease (CKD-5)…

Patient Identification and Management in Axial Spondylarthritis and Psoriatic Arthritis

Experts Antoni Chan, Consultant Rheumatologist and Associate Medical Director, Royal Berkshire NHS Foundation, UK, and Laura Coates…

Pursuing a pathway of preventative medicine

A world without illness or disease sounds like a far-off fantasy, but some players in the pharmaceutical industry are investigating how to transform this vision into a reality.

Pharma in China

As China enters the year of the tiger – a symbol of strength and bravery – GOLD journeys to this powerhouse nation to explore how it has become the second largest pharmaceutical market in the world

Renewed focus on patient adherence

Patient adherence is the focus of a new project launched by the Innovative Medicines Initiative (IMI) and led by Pfizer.